Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + BEGEV in Relapsed/Refractory Hodgkin's Lymphoma
NCT05300282Phase 2Active, not recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in Hodgkin lymphoma (HL), sponsored by Fondazione Italiana Linfomi. Started Feb 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT05300282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300282.